



UF | College of Medicine UNIVERSITY *of* FLORIDA

AUGUST 2023

IMPACT REPORT FOR STOP CHILDREN'S CANCER, INC.



TABLE OF CONTENTS

PG 2	Letter from the Chief
PG 3	Stop Children's Cancer, Inc. Giving History
PG 6	Stop Children's Cancer, Inc. Return on Investment Summary
PG 7	Fiscal Year 2023 Clinical Trials Recap
PG 8	Meet our Team
PG 9	Division of Pediatric Hematology & Oncology Attending Physicians
PG 16	Looking Forward
PG 17	Patient Story – No Time 'Fore' Cancer
PG 19	Appendix A – Publications




WE BELIEVE IN PROTECTING TOMORROW'S FUTURES, TODAY!

In the Division of Pediatric Hematology & Oncology we strive every day to meet our mission to provide the finest, most compassionate care to children suffering from childhood cancers and blood disorders. We have been blessed over the 42 years that the mission of Stop Children's Cancer to prevent, control and cure childhood cancers aligns so closely to ours, and that you have had the faith in our team to invest philanthropically in our work.

The impact of your support has reached beyond the dollars directly donated by Stop Children's Cancer. We have been able to leverage your support and expand our funding through multiple sources. Enclosed you will find updates on the work our team has been advancing in the battle against childhood cancers. I hope that you enjoy reviewing this impact report, and feel immensely proud of the work we've accomplished together.

Thank you again for all you have done to help move medicine forward.

Sincerely,



William "Bill" Slayton, MD
Chief, Division of Pediatric Hematology and Oncology
Professor, Department of Pediatrics, University of Florida College of Medicine



STOP CHILDREN'S CANCER, INC. GIVING HISTORY

The direct giving from Stop Children's Cancer, Inc. over our longstanding relationship has made a substantial impact on the research being done to better diagnose, treat, and ultimately cure pediatric cancer. Many researchers that received seed funding from Stop Children's Cancer showed significant enough findings to apply for and receive grant funding from multiple other sources. UF Health pediatric researchers leveraged the funding from Stop Children's Cancer to grow their projects –helping to achieve their key milestones and attract even more funding. That additional funding allows them to scale their research, hire key talent to aide in the research, and ultimately bring them closer to the goal of finding a cure for pediatric cancer. None of this would be possible without the faith from Stop Children's Cancer in our team to make the much-needed initial investments. Thank you.

DATE	OPPORTUNITY	AMOUNT
1985-89	Grant for scientific equipment and cancer research	\$50,000
	Grant for pilot project using magnetic Bead Process to extract cancer cells from bone marrow, a major breakthrough in the fight against leukemia	
	Grant to establish four laboratories	
1990	Research equipment to enhance efficiency in research process: Fluorescence Activated Cell Sorter Epics II Flow Cytometer and a Gene Machine	\$100,000
1991	Grant: Stem Cell & Tumor Biology	\$100,000
1992	Grant to establish Southeastern Brain Tumor Tissue Bank in the Pediatric Neuro-Oncology Division	\$50,000
1995-96	Dr. William Slayton's two-year fellowship	\$80,000
1996-97	Grant to study ALL	\$82,662
	Grant to study Glioma Brain Tumors	
	Grant to study Pediatric & Adolescent Osteosarcoma	
1999	1st Annual Visiting Scholar: Dr. Curt Civin, John Hopkins	\$3,000
	Grants to support pediatric cancer projects	\$50,000
2000	2nd Annual Visiting Scholar: Dr. Jonathan Finlay, NYU	\$2,500
	Grant in the Department of Orthopaedic Surgery to study Ewing's Sarcoma	\$10,000
2001	Grant to support Dr. David Bloom for study of Malignant Glioma	\$50,000
	Grant to support Dr. Mingli Yang for study of Acute Promyelocytic Leukemia	
	Grant to support promising new investigator	
2002	Grant to support Dr. David Bloom for year-two study of Malignant Glioma	\$50,000
	Grant to support Dr. Mingli Yang for year-two study of Acute Promyelocytic Leukemia	



STOP CHILDREN'S CANCER, INC. GIVING HISTORY

DATE	OPPORTUNITY	AMOUNT
2003	Funds for annual nine-year commitment for future grant applications	\$100,000
	Grant to support Dr. Stephen Hunger for study of leukemia	\$75,000
	Grant to support Dr. C. Parker Gibbs for study of osteosarcoma	
	Dearest Howard and Laurel, There are not words to describe the amount of effort and love you have poured into Stop Children's Cancer. Your support of my early research in osteosarcoma was instrumental in garnering NIH funding, papers, wonderful collaboration across disciplines, new colleagues and a contribution to the knowledge of this terrible cancer of kids. None of this would have been possible without you. I wish you the very best and thank you, always! Parker	
	Grant to support Dr. Mingli Yang for study of osteosarcoma	
2004	Grant to support Dr. Stephen Hunger for study of leukemia	\$76,000
	Grant to support Dr. Amir H. Shahlaee for evaluation of IDO expression in lymph nodes	
	Grant to support Dr. Susan Staba for study of QOL following stem cell transplant	
2006	Establishment of the Stop Children's Cancer/ Bonnie R. Freeman Professorship for Pediatric Oncology Research FACULTY THAT HAVE HELD THE PROFESSORSHIP <ul style="list-style-type: none"> • David Muir IV, PhD • Burak Gumuscu, MD, PhD • Biljana Horn, MD • Elias Sayour, MD, PhD 	\$1,000,001
2007	Match from State of Florida Trust Fund	\$750,001
	Grant to support Dr. David Muir to test photodynamic therapy treatment of neurofibromatosis tumors	\$25,000
2008	Grant to support Dr. Xinming Deng for study of ALL	\$150,000
	Grant to support Dr. Jianrong Lu for study of ALL I am very grateful for Stop Children's Cancer funding for our research in 2008-2009. This fund allowed us to explore a new idea at that time and generate key preliminary experimental results. The project subsequently received a grant from Florida Department of Health, and led to a publication in "Oncogene" (T Lin, A Ponn, X Hu, BK Law, J Lu. Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition. Oncogene 29, 4896-4904, 2010) (Stop Children's Cancer was acknowledged). According to Google Scholar, this paper has already been cited over 300 times. I very much appreciate the support from Stop Children's Cancer. Thank you. Jianrong	
	Grant to support Dr. Daging Liao for study of neuroblastoma	

STOP CHILDREN'S CANCER, INC. GIVING HISTORY


DATE	OPPORTUNITY	AMOUNT
2009	Grant to support Dr. Eric Laywell for study of Pediatric brain cancer	\$150,000
	Grant to support Dr. Shoudong Li for study of ALL	
	Grant to support Dr. Daiqing Liao for study of neuroblastoma	
2010	Grant to support Dr. Lizi Wu for study of ALL	\$75,000
	Grant to support Dr. Eric Bartee for study of treatments of high-risk pediatric cancer cells	
	Establishment of the Stop Children's Cancer/Bonnie R. Freeman Clinical Trials and Innovative Therapies Program Fund	\$1,050,000
2013	Gift to UF Health Physical Therapy Pediatric Oncology Division in honor of Whitney, daughter of Barbara & Whitney Bour, a cancer survivor who was completing a pediatrican fellowship in neonatology at St. Louis Children's Hospital	\$1,500
2014	Gift to UF Health Palliative Care Program to support the work of Dr. Joanne Lagmay	\$20,000
2016	Stop Children's Cancer/Sam & Ina Gross Memorial Lectureship	\$57,195.55
2018	Renewed support of Stop Children's Cancer/Bonnie R. Freeman Clinical Trials and Innovative Therapies Program Fund	\$1,000,000
	Stop Children's Cancer/Sam & Ina Gross Memorial Lectureship	\$10,725.44
2019	Stop Children's Cancer/Sam & Ina Gross Memorial Lectureship	\$9,565.44
	Stop Children's Cancer/Lyrics for Life Jeffrey A. Block Research Award given to support Dr. Paul Castillo for study of leukemia and lymphoma immune technologies	\$100,000
2020	Stop Children's Cancer/Lyrics for Life Jeffrey A. Block Research Award given to support Dr. Paul Castillo for study of leukemia and lymphoma immune technologies	\$100,000
2022	Stop Children's Cancer/Lyrics for Life Jeffrey A. Block Research Award given to support Dr. Paul Castillo for study of leukemia and lymphoma immune technologies	\$100,000
2023	Renewed support of Stop Children's Cancer/Bonnie R. Freeman Clinical Trials and Innovative Therapies Program Fund	\$1,000,000
	Establishment of the Stop Children's Cancer/Kimberly H. Flaitz Research Grant	
TOTAL STOP CHILDREN'S CANCER DIRECT SUPPORT		\$6,478,150.43

STOP CHILDREN'S CANCER, INC. RETURN ON INVESTMENT SUMMARY



Notes:

1. Dollar amounts reflect additional funding received due to Stop Children's Cancer direct funding.
2. Grants and clinical trials that were open prior to 2016, but active in that year are counted in the 2016 numbers (< and 2016).
3. Funding is based on NCI guidelines of annual cancer-relevant direct costs and pulled from the annual funding data table.
4. Clinical trials are all clinical research projects of which the faculty member is the PI.
5. Accruals are from all clinical research projects the faculty member is the PI of, regardless of who puts the patient on the trial.



FISCAL YEAR 2023 CLINICAL TRIALS RECAP

Available Pediatric Studies = 43

- This includes 5 investigator initiated studies

Studies Coming Soon

- 5 COG and/or industry studies
- 3 investigator initiated treatment studies

Supported Basic Science Studies = 4

Children's Oncology Group Registry/Biology Studies = 3

- Required for participation in COG treatment studies
- Collecting long term follow-up data only = 20

Late Effect Screening/Prevention Studies = 3

- Including 1 IIT

Available Adolescent/Adult Studies = 10

- These are studies that allow our patients age 18-25 years to participate
- Phase 1 studies for relapsed solid tumors = 3
- Adult heme/benign studies = 7

Expanded Access FDA IND Request Supported = 5

- For patients who need access to a drug or cellular therapy not commercially available

Since January, we have enrolled 13 patients on therapy trials, 31 on COG registry/biology, 13 on Screening/Prevention, and 6 on our local basic science studies – for a total of 63 consented to a study.

DIVISION OF PEDIATRIC HEMATOLOGY & ONCOLOGY ATTENDING PHYSICIANS MEET OUR TEAM

Matthew Cascio, DO
Assistant Professor

Paul Castillo Caro, MD
Assistant Professor

Mansi Dalal, MD
Clinical Assistant Professor

Biljana Horn, MD
Clinical Professor

Joanne Lagmay, MD
Associate Professor

John Ligon, MD
Assistant Professor


Jordan Milner, MD
Assistant Professor

Elias Sayour, MD, PhD
Assistant Professor


William Slayton, MD
Professor and Division Chief

Brian Stover, MD
Assistant Professor

Tung Wynn, MD
Clinical Associate Professor



DIVISION OF PEDIATRIC HEMATOLOGY & ONCOLOGY ATTENDING PHYSICIAN



Matthew Cascio, DO
Assistant Professor

Matthew Cascio, DO, is an assistant professor in the division of hematology and oncology in the department of pediatrics in the University of Florida College of Medicine.

After he achieved his bachelor's degree in sociology from the Ohio State University in Columbus, Ohio, Dr. Cascio graduated with his doctor of osteopathy degree from Nova Southeastern University College of Osteopathic Medicine in Fort Lauderdale, Florida. He then pursued his residency in pediatrics at Penn State University College of Medicine in Hershey, Pennsylvania. The following year, Dr. Cascio completed his fellowship in the division of pediatric hematology and oncology at UF Health Shands Children's Hospital.

Dr. Cascio is board-certified in pediatrics by the American Board of Pediatrics. Throughout his academic career, he has been involved with various associations, such as the American Academy of Pediatrics and the Children's Oncology Group. He has also received numerous honors, like the Sarcoma Foundation of America Award and Douglas J. Barrett Fellow Research Award. Dr. Cascio has extensive experience in research, with his interests including brain tumors, immunotherapy and programmatic development.

Dr. Cascio currently serves as the interim clinical director of pediatric neuro-oncology, and he is passionate about childhood advocacy, mentorship and clinical research.



Paul Castillo Caro, MD
Assistant Professor

Paul Castillo, MD, is an assistant professor of pediatrics and physician-scientist of the T Cell Engineering Laboratory of the Pediatric Cancer Immunotherapy Initiative and the Brain Tumor Immunotherapy Program at the University of Florida. He serves as a member of the UF Data Integrity and Safety Committee, UF College of Medicine Scientific Review Committee, and as liaison of the UF Health Cancer Center Community Outreach Engagement Council.

Dr. Castillo received his medical degree from the Universidad Peruana Cayetano Heredia, Lima, Peru. He completed his pediatric residency at the Riley Hospital for Children – Indiana University. Next, he trained in hematology-oncology with additional focus on stem cell transplantation and cellular therapy at the Texas Children's Cancer and Hematology Centers – Center for Cell & Gene Therapy – Baylor College of Medicine. At the University of Florida, his translational efforts are focused on developing new pipeline technologies that include systemic activation of innate and adaptive immunity to synergize and enhance CAR T cell activity against metastatic osteosarcoma.

Dr. Castillo's research has received multiple awards including the Hyundai Hope on Wheels Young Investigator award, the American Brain Tumor Association Discovery award, the Florida Department of Health Live Like Bella Discovery award, the Gabrielle's Angel Cancer Research Foundation award, and an institutional KL2 award. His research endeavors are additionally supported by Stop Children's Cancer.

I am writing to express my heartfelt gratitude for Stop Children's Cancer's ongoing support of pediatric cancer research. Your partnership and compassion are invaluable in our mission to find better treatments and ultimately a cure for childhood cancer. On behalf of our faculty, staff and the patients we serve, I want to extend our sincerest thanks for your contribution.


Your donations have directly impacted the lives of children and families affected by pediatric cancer. With your support, we will be able to continue to fund vital research initiatives, clinical trials, and innovative treatments, ensuring that every child receives the best possible care. Your commitment to our cause is truly making a difference and giving hope to those facing unimaginable challenges.

We understand that your decision to donate was driven by a deep empathy for the young patients and their families who battle this devastating disease. Your kindness and compassion demonstrate an incredible understanding of the urgency and importance of pediatric cancer research. Your belief in our work is a source of motivation for our dedicated team of researchers, doctors, and volunteers.

I would like to assure you that the financial support from Stop Children's Cancer will be used judiciously and efficiently to maximize its impact. Once again, thank you for your incredible generosity. Your support is a testament to your compassion and commitment to making a positive difference in the lives of children and their families. Together, we can continue to create a brighter future for those affected by pediatric cancer.

With deepest gratitude,

Paul Castillo Caro, MD
Assistant Professor, Department of Pediatrics
University of Florida College of Medicine




DIVISION OF PEDIATRIC HEMATOLOGY & ONCOLOGY ATTENDING PHYSICIAN



Mansi Dalal, MD
Clinical Assistant Professor

Mansi Dalal, MD, grew up in Silver Spring, Maryland. She graduated from the University of Maryland with a degree in Biochemistry. She then performed research for several years at the Bloomberg School of Public Health/Johns Hopkins University prior to entering medical school. She graduated from medical school magna cum laude and completed her residency in Pediatrics in Baltimore, Maryland. Dr. Dalal then completed a fellowship in pediatric Hematology/Oncology at the University of Florida. She has remained at UF as a faculty member within the department of pediatrics and specializes in leukemia/lymphoma and hematopoietic stem cell transplantation.



Biljana Horn, MD
Clinical Professor, Retired

Biljana Horn, MD, previous director of the Pediatric Bone Marrow Transplant and Cell Therapy Program, earned her medical degree at the University of Zagreb. She completed a pediatric residency at Case Western Reserve University, followed by a fellowship in pediatric hematology/oncology at the National Cancer Institute and another in pediatric neuro-oncology at UCSF.

Dr. Horn's research efforts focused on developing reduced intensity conditioning regimens for children, improving outcomes for children with brain tumors by using high-dose chemotherapy and stem cell support, reducing transplant-related mortality, reducing relapse after transplant and developing regimens for transplant of newborns with immune deficiencies. With grant support from the Live Like Bella Foundation, Dr. Horn organized the transplant programs in Florida into a quality improvement and research consortium. Dr. Horn received a second grant from Live like Bella Foundation to run a clinical trial within the Florida Consortium using a new cell sorting technology in patient receiving stem cell transplants to reduce graft versus host disease and enhance the anticancer effect of the transplant.

She is a member of the AAP, the Children's Oncology Group, the American Society of Hematology, the American Society for Blood and Marrow Transplantation, the Pediatric Blood and Marrow Transplant Consortium and the Foundation for the Accreditation of Cellular Therapy.

Dr. Horn served as the Stop Children's Cancer/Bonnie R. Freeman Professor for Pediatric Oncology Research until her retirement.

DIVISION OF PEDIATRIC HEMATOLOGY & ONCOLOGY ATTENDING PHYSICIAN



Joanne Lagmay, MD


Associate Professor

STOP! Children's Cancer of Palm Beach County, Inc. Professor in Pediatric Oncology

Joanne Lagmay, MD, is board-certified in general pediatrics and pediatric hematology/oncology. Her main focus has been the multidisciplinary treatment of pediatric solid tumors, specifically pediatric sarcoma of the bone and soft tissue. She also has special interest in pediatric palliative care.

Dr. Lagmay participates in several national professional societies and committees, including the Children's Oncology Group, American Society of Pediatric Hematology and Oncology, American Society of Hematology, Connective Tissue Oncologic Society, and Stop Children's Cancer. Her practice integrates translational research in targeted radionuclide therapies for osteosarcoma in collaboration with UF Veterinary Medicine, Biomedical Engineering, Chemistry, Material Science Engineering and Radiation Oncology. Her direct collaboration with pediatric oncology colleagues in Florida has resulting phase I clinical trials for pediatric cancer patients in the state.

Dr. Lagmay came to UF in 2009 from Nationwide Children's Hospital, The Ohio State University where she was a fellow in pediatric hematology/oncology. She did her pediatric residency training at the Children's Hospital of Monmouth in New Jersey, where she also served as chief resident.



John Ligon, MD

Assistant Professor

John Ligon, MD, is an assistant professor in the department of pediatrics at the University of Florida College of Medicine. He earned his medical degree from the Baylor College of Medicine in Houston, completed his residency in pediatrics at the University of Texas Southwestern Medical Center in Dallas, and pursued a fellowship in pediatric hematology and oncology at Johns Hopkins University and the National Cancer Institute in Maryland. In the following years,

he completed a senior fellowship in pediatric immunotherapy at the National Cancer Institute and another in pediatric sarcoma at Johns Hopkins University.

Dr. Ligon is board-certified in both general pediatrics and pediatric hematology and oncology by the American Board of Pediatrics. In addition to his numerous original research publications and editorial review appointments, he is a member of various professional societies, such as the Children's Oncology Group and the American Association for Cancer Research. Dr. Ligon has been honored with a variety of awards for his research skills and academic excellence. His research interests include immunotherapy, tumors and bloodstream infections.

Dr. Ligon is a member of the Pediatric Cancer Immunotherapy Initiative (PCI2) at the University of Florida, where he serves as a translational partner with collaborators, Drs. Elias Sayour and Paul Castillo, to advance new treatments which harness the power of the immune system into early phase pediatric clinical trials. His work is supported by a number of foundations and organizations including Stop Children's Cancer, Inc., the V Foundation, Hyundai Hope on Wheels, the Society for Immunotherapy of Cancer, the National Pediatric Cancer Foundation, the Pediatric Cancer Research Foundation, MIB Agents and the Children's Miracle Network.

DIVISION OF PEDIATRIC HEMATOLOGY & ONCOLOGY ATTENDING PHYSICIAN



Jordan Milner, MD
Assistant Professor

Jordan Milner, MD, is a clinical assistant professor in the division of pediatric hematology oncology at the University of Florida College of Medicine and director of the Pediatric Bone Marrow Transplant (BMT) and Cellular Therapy Program.

In medical school, she was a member of the Global Scholar Program at St. George's University School of Medicine for medical students who exhibit academic excellence. She completed her pediatric residency and chief year at Memorial University Medical Center in Savannah, GA, and went on to complete a fellowship in pediatric hematology/oncology at Maria Fareri Children's Hospital at Westchester Medical Center in Valhalla, NY.

Dr. Milner has dedicated her research to stem cell graft manipulation and virus specific cytotoxic T-lymphocytes. At the Pediatric Blood & Marrow Transplantation and Cell Therapy Program, she is currently working to bring alpha/beta T cell and B cell depletion for allogeneic stem cell transplants to UF and looks forward to opening several trials utilizing this graft manipulation.



Elias Sayour, MD, PhD
Assistant Professor
Stop Children's Cancer/Bonnie R. Freeman Professor for Pediatric Oncology Research

Elias Sayour, MD, PhD, is an assistant professor in the UF departments of neurosurgery and pediatrics and the incoming Stop Children's Cancer/Bonnie R. Freeman Professor for Pediatric Oncology Research. He is also a principal investigator of the ribonucleic acid engineering laboratory at the Preston A. Wells, Jr. Center for Brain Tumor Therapy. He received his bachelor's

degree from Fordham University, his medical degree from the University of Buffalo and his doctorate from Duke University.

He completed his residency in pediatrics at Cohen's Children's Medical Center in New York and his fellowship at Duke University Medical Center. During his fellowship training, he completed a two-year National Institutes of Health research fellowship in cancer biology and developmental therapeutics. His primary research focus is developing tumor RNA loaded nanocarriers to re-direct host immunity against pediatric brain tumors.

Dr. Sayour is an NIH-funded investigator focused on developing new nanotech vaccines to reprogram the immune system against cancer cells. He is investigating the use of personalized nanoparticles small enough to deliver essential information to the immune system educating it reject pediatric cancer. Currently his group is investigating the safety and efficacy of this novel vaccine formulation in canines with malignant brain tumors before translation into dedicated human studies.

Dr. Sayour's work has been nationally recognized by the American Society of Pediatric Hematology-Oncology, National Institutes of Health, and U.S. Department of Defense. He has been the recipient of the Hyundai Hope on Wheels Hope Award, St. Baldrick's Scholar Award, and the American Brain Tumor Association Discovery Award. Dr. Sayour is board-certified in general pediatrics and pediatric hematology-oncology. He has presented his work at several national meetings and is a member of the Children's Oncology Group, Society of Neuro-Oncology and the American Society of Pediatric Hematology-Oncology.

DIVISION OF PEDIATRIC HEMATOLOGY & ONCOLOGY ATTENDING PHYSICIAN



William Slayton, MD
Professor and Division Chief

Called “Dr. Bill,” by his patients and colleagues, William Slayton, MD, joined the division of pediatric hematology and oncology in 2002, with a focus on platelet disorders and leukemia. He received his bachelor’s degree in biology from Oberlin College and his medical degree from the University of Florida. He also completed a pediatric internship, pediatric residency, and pediatric fellowship at UF. Dr. Slayton is now the chief of the division, and also chair’s the Children’s Oncology Group clinical trial AALL0622, Improved Targeted Tyrosine Kinase Therapy for Ph+ Acute Lymphoblastic Leukemia.

As a pediatric oncologist Dr. Slayton has worked to improve the treatments for children with leukemia. He has been fortunate to have the opportunity to work on and then lead clinical trials using new targeted therapies for children with high risk leukemia. His laboratory has interest in how normal and leukemic stem cell interact with the bone marrow microenvironment. His current projects are focused on developing better therapies for Ph+ Acute Lymphoblastic Leukemia and Infant Leukemia.

His goal is to be a great teacher and lead the division and department to provide the best care for their patients. He has assembled a team of like-minded providers who want to do the very best for our kids.



Brian Stover, MD
Assistant Professor

Brian Stover, MD, earned his medical degree from the University of Texas Medical School at Houston. Soon after, he began his residency in pediatrics at the University of Florida and continued his career at UF, completing a fellowship in pediatric hematology/oncology.

Dr. Stover joined the UF faculty in 2019 as an assistant professor in the department of pediatrics.

His current research focuses on solid tumor immunotherapy, including the use of personalized RNA-nanoparticle vaccines in metastatic osteosarcoma.

Dr. Stover is board-certified in pediatrics by the American Board of Pediatrics and is board-eligible in hematology/oncology. He is a recipient of the Henry A. Kokomoor award for Scientific Discovery and is a member of the American Academy of Pediatrics, the Children’s Oncology Group and the American Society of Pediatric Hematology-Oncology.

DIVISION OF PEDIATRIC HEMATOLOGY & ONCOLOGY ATTENDING PHYSICIAN



Tung Wynn, MD
Clinical Associate Professor

Tung Wynn, MD, attended Northeastern Ohio Medical University for medical school and stayed at Children's Hospital Medical Center of Akron to complete his pediatric residency. He then completed his fellowship in Pediatric Hematology/Oncology at Ohio State University and Nationwide Children's Hospital. Dr. Wynn became an attending physician in Pediatric Hematology/Oncology at St. Joseph's Children's Hospital of Tampa in 2003.

He joined the University of Florida faculty in 2012 as an assistant professor in the division of Pediatric Hematology/Oncology. He is also the director of the UF Pediatric Hemostasis Program and the UF Pediatric Cancer Survivorship Program. Dr. Wynn currently holds professional memberships with the American Society of Hematology, Florida Medical Association, Children's Oncology Group, American Society of Clinical Oncology, American Society of Pediatric Hematology/Oncology and the American Academy of Pediatrics.



LOOKING FORWARD

The mission of our Pediatric Hematology & Oncology team is to provide the finest, most compassionate care to children suffering from childhood cancers and blood disorders. Staffing top pediatric specialists, using the latest kid-friendly expertise and making innovative strides in pediatric research, we dedicate ourselves to the health and well-being of our patients

Pediatric cancer research plays a critical role in improving the understanding, diagnosis, treatment, and outcomes for children diagnosed with cancer. Over the years, significant progress has been made, leading to increased survival rates for many pediatric cancers. However, there is still much to be done to further advance the field. Here are some areas of ongoing research and promising developments in pediatric cancer:

1. **Precision Medicine:** Precision medicine focuses on tailoring treatments to a patient's specific genetic and molecular profile. This approach has shown great promise in pediatric cancer research. By analyzing the unique genetic makeup of a child's tumor, researchers can identify targeted therapies that may be more effective and less toxic than traditional treatments.
2. **Immunotherapy:** Immunotherapy has revolutionized cancer treatment, including pediatric cancers. This approach harnesses the power of the immune system to recognize and attack cancer cells. Immunotherapies like CAR-T cell therapy and immune checkpoint inhibitors have shown remarkable success in treating certain pediatric cancers, such as acute lymphoblastic leukemia (ALL) and neuroblastoma. Ongoing research focuses on new therapies using vaccines to improve survival in aggressive pediatric cancers such as glioblastoma, diffuse pontine glioma and relapsed osteosarcoma.
3. **Long-Term Side Effects and Survivorship:** While improved treatments have led to higher survival rates, pediatric cancer survivors often face long-term side effects from their treatments. Research efforts are focused on understanding and mitigating these side effects to improve the quality of life for survivors. This includes studying the impact of treatments on organ function, fertility, neurocognitive development, and mental health.
4. **Collaborative Research Initiatives:** Many research institutions, organizations, and advocacy groups are actively collaborating to accelerate pediatric cancer research. These collaborations aim to pool resources, share data, and streamline clinical trials to bring new treatments to children faster.
5. **Rare and High-Risk Pediatric Cancers:** Research is also focused on rare and high-risk pediatric cancers that have limited treatment options. By studying the biology and genetics of these cancers, researchers hope to identify new therapeutic targets and develop novel treatments.
6. **Supportive Care:** In addition to treating the cancer itself, researchers are exploring supportive care interventions to manage the physical and emotional challenges faced by children with cancer and their families. This includes addressing pain management, psychosocial support, and enhancing the overall well-being of pediatric cancer patients.

It's important to note that research progress is a dynamic field, and new breakthroughs and discoveries are being made regularly. Collaborative efforts between researchers, clinicians, policymakers, and advocacy groups are crucial for advancing pediatric cancer research and improving outcomes for children affected by cancer.

We COULD NOT do this without your partnership. Thank you again for believing in our mission and working so diligently to support the research being done by the Pediatric Hematology & Oncology team at UF Health Shands Children's Hospital.

As a young teenager, Savannah was an accomplished student-athlete who played on her high school's girls golf team. She had been practicing with the team and competing in golf matches when she noticed an ongoing cough. Thinking it was allergies, 16-year-old Savannah continued to play. After an off-and-on fever began to develop, her mom urged her to go to their neighborhood urgent care center.

There she was told she had a viral infection and to return if her symptoms didn't improve within a week. One week later, Savannah was still coughing, so she returned to the urgent care center — but only after she finished another round of golf.

She was tested for COVID-19 and with three golf matches coming up, she was ecstatic the result was negative. But then health care providers took a chest X-ray that revealed a massive spot in the middle of her chest. Next, they ordered a CT scan and blood tests.

After Savannah's blood test results showed high levels of white blood cells, she was told she had to go to the emergency room immediately. Soon after, an ambulance rushed Savannah and her mother from the urgent care center to UF Health Shands Children's Hospital.

With so much activity swirling around her all at once, Savannah couldn't quite grasp what was happening. It wasn't until she was alone in the restroom that she finally broke down and cried. From the way the staff looked at her, she understood that her chest scan revealed something terribly wrong.

In the emergency room, Savannah was asked many questions about her symptoms, causing her to mentally replay a series of thoughts that she was now forced to pay more attention to. She had been short of breath and her cough was persistent — things she attributed to seasonal allergies. There was also sharp pain in her upper shoulder area, a pain she attributed to her golf game. She also remembered she had endured several evenings of night sweats that left her clothes and bed sheets drenched.

From the ER, Savannah was transferred and admitted to the pediatric intensive care unit, or PICU, of UF Health Shands Children's Hospital.

Before having a second CT scan, she met the University of Florida College of Medicine Department of Pediatrics' chief of



Savannah receiving outpatient infusion treatments.



Savannah preparing to receive a peripherally inserted central catheter (PICC) line.

pediatric hematology/oncology, Dr. William Slayton, who introduced himself and informed Savannah that she likely had cancer.

"What he was talking to me about was very intimidating, but I soon realized that he's a very personable person who explained things very easily to me so that I could understand my condition and diagnosis better," Savannah said. "We really bonded over the fact that I've had such a great golf game the entire time despite playing with such a small airway," Savannah continued.

Health care providers performed four biopsies near her airway right at her bedside.

Savannah was diagnosed with stage 2B Hodgkin lymphoma, a type of cancer that affects the body's lymph tissue. Lymph tissue is found in the lymph nodes, spleen, tonsils, liver, bone marrow and other organs of the immune system.

Hodgkin's lymphoma is a very curable form of cancer that tends to affect teenagers like Savannah, as well as young adults. While the cure rates are excellent and approach 85%, the treatments are hard. Patients with Hodgkin's disease can later on develop breast cancer, coronary artery disease, pulmonary fibrosis and infertility. A recent clinical trial available at UF Health substituted a new targeted therapy called brentuximab vedotin for an older medication called bleomycin, a drug that causes pulmonary fibrosis, a disorder causing stiff lungs with poor function. The patients who received brentuximab had a 10% better cure rate and avoided the lung toxicity of the prior standard treatment.

In September of 2021, Savannah had her first chemotherapy treatment. Over the next eight weeks, she underwent numerous inpatient chemotherapy treatments and outpatient infusions, including a 21-day cycle of chemotherapy that took over three hours each time.

The holidays came early for Savannah as she celebrated her last chemotherapy treatment just before Christmas. After seeing no activity in her chart, Savannah underwent proton therapy treatment at UF Health Proton Therapy Institute in Jacksonville and was able to ring the Aud's Chime of hope following her treatment.



Savannah and Dr. Slayton at the 28th Bob Dooley Invitational benefiting Stop Children's Cancer.

Soon, her scans came back promising and she was able to ring the bell just outside the UF Health Infusion Center – Medical Plaza, as well as the bell in the UF Health Children's Healing Garden in front of a group of excited singing nurses, friends and family.

Savannah credits UF Health's nurses and Dr. Slayton for helping to make her health journey as pleasant as possible. Savannah's faith in God, and having her family with her every step of the way, was instrumental in helping her feel surrounded by support and encouragement.

While Savannah didn't get the opportunity to play golf during her junior season, she returned to play with her team her senior year — earning third place individually in the district tournament and celebrating as her team won overall.

Today, at 18 years-old, Savannah is a high school graduate and plans to play golf in college while pursuing a degree in sports journalism. Her goal? To help inspire others through the triumphant stories of athletes just like her.

APPENDIX A – PUBLICATIONS

MATTHEW CASCIO, DO		
DATE	TITLE	JOURNAL
2017 Nov	A Case Presentation: Rare Occurrence of an Adolescent Male Presenting With an ATRT and Simultaneous Low-grade Glioneuronal Tumor.	<i>Journal of pediatric hematology/ oncology</i>
2020 Feb	GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas.	<i>American journal of cancer research</i>
2021 Feb	Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.	<i>Veterinary immunology and immunopathology</i>
2021 Mar	Novel application of single-cell next-generation sequencing for determination of intratumoral heterogeneity of canine osteosarcoma cell lines.	<i>Journal of veterinary diagnostic investigation</i>
2022 Jun	CART Cell Locomotion in Solid Tumor Microenvironment.	<i>Cells</i>

PAUL CASTILLO CARO, MD		
DATE	TITLE	JOURNAL
2018 Jul	Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient.	<i>Blood advances</i>
2018 Oct	Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.	<i>Nano letters</i>
2019 Jun	A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.	<i>Blood advances</i>
2019 Sep	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.	<i>Biology of blood and marrow transplantation</i>
2020 Mar	Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study.	<i>The Lancet. Haematology</i>
2020 May	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.	<i>Haematologica</i>
2020 Aug	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.	<i>Biology of blood and marrow transplantation</i>
2021 Feb	Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes.	<i>Transplantation and cellular therapy</i>
2021 Feb	Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome.	<i>Nature communications</i>
2021 Jun	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis.	<i>Blood</i>
2021 Aug	Pediatric HCT in Florida (2014 -2016): A report from the FPBCC.	<i>Pediatric transplantation</i>

2021 Sep	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.	<i>Bone marrow transplantation</i>
2021 Sep	Stoss therapy is safe for treatment of vitamin D deficiency in pediatric patients undergoing HSCT.	<i>Bone marrow transplantation</i>
2021 Oct	Race as a factor in donor selection and survival of children with hematologic malignancies undergoing hematopoietic stem cell transplant in Florida.	<i>Pediatric blood & cancer</i>
2021 Nov	Diagnostic work-up for severe aplastic anemia in children: Consensus of the North American Pediatric Aplastic Anemia Consortium.	<i>American journal of hematology</i>
2021 Dec	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.	<i>Bone marrow transplantation</i>
2022 Jan	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.	<i>Blood advances</i>
2022 May	Effects of immune checkpoint blockade on antigen-specific CD8+ T cells for use in adoptive cellular therapy.	<i>Microbiology and immunology</i>
2022 Jun	CART Cell Locomotion in Solid Tumor Microenvironment.	<i>Cells</i>
2022 Jul	Vitamin D Supplementation: Association With Serum Cytokines in Pediatric Hematopoietic Stem Cell Transplantation.	<i>Frontiers in pediatrics</i>
2022 Aug	Impact of Adequate Day 30 Post-Pediatric Hematopoietic Stem Cell Transplantation Vitamin D Level on Clinical Outcome: An Observational Cohort Study.	<i>Transplantation and cellular therapy</i>
2022 Aug	Natural Killer Cell Alloreactivity Predicted By Killer Cell Immunoglobulin-Like Receptor Ligand Mismatch Does Not Impact Engraftment in Umbilical Cord Blood and Haploidentical Stem Cell Transplantation.	<i>Transplantation and cellular therapy</i>
2022 Oct	Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.	<i>Leukemia</i>
2022 Dec	Evolution and Revolution of Imaging Technologies in Neurosurgery.	<i>Neurologia medico-chirurgica</i>

MANSI DALAL, MD		
DATE	TITLE	JOURNAL
2020 Oct	Incidence and Risk Factors for 30-Day Readmission after Inpatient Chemotherapy among Acute Lymphoblastic Leukemia Patients.	<i>Healthcare (Basel, Switzerland)</i>

BILJANA HORN, MD		
DATE	TITLE	JOURNAL
2018 Jun	KRAB-ZFP Repressors Enforce Quiescence of Oncogenic Human Herpesviruses.	<i>Journal of virology</i>
2019 Feb	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation.	<i>Biology of blood and marrow transplantation</i>
2019 Feb	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.	<i>Biology of blood and marrow transplantation</i>

2019 May	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.	<i>Bone marrow transplantation</i>
2019 Jun	A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.	<i>Blood advances</i>
2020 Mar	Postautologous stem cell transplantation engraftment syndrome: Improved treatment and outcomes.	<i>Clinical transplantation</i>
2020 May	Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children.	<i>Biology of blood and marrow transplantation</i>
2020 Aug	Parvovirus B19 infection masquerading as relapsed acute lymphoblastic leukaemia following haematopoietic stem cell transplantation.	<i>BMJ case reports</i>
2021 May	Potential Risk Factors Associated With Graft Failure of Haploidentical Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease.	<i>Journal of pediatric hematology/ oncology</i>
2021 Aug	Pediatric HCT in Florida (2014 -2016): A report from the FPBCC.	<i>Pediatric transplantation</i>
2021 Sep	Stoss therapy is safe for treatment of vitamin D deficiency in pediatric patients undergoing HSCT.	<i>Bone marrow transplantation</i>
2021 Oct	Race as a factor in donor selection and survival of children with hematologic malignancies undergoing hematopoietic stem cell transplant in Florida.	<i>Pediatric blood & cancer</i>
2022 Feb	Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia.	<i>Transplantation and cellular therapy</i>
2022 Jul	Vitamin D Supplementation: Association With Serum Cytokines in Pediatric Hematopoietic Stem Cell Transplantation.	<i>Frontiers in pediatrics</i>
2022 Aug	Impact of Adequate Day 30 Post-Pediatric Hematopoietic Stem Cell Transplantation Vitamin D Level on Clinical Outcome: An Observational Cohort Study.	<i>Transplantation and cellular therapy</i>
2022 Nov	Prospective Validation and Refinement of a Population Pharmacokinetic Model of Fludarabine in Children and Young Adults Undergoing Hematopoietic Cell Transplantation.	<i>Pharmaceutics</i>

JOANNE LAGMAY, MD		
DATE	TITLE	JOURNAL
2016 Jan	Left Ventricular Metastasis in Neuroblastoma: A Case Report.	<i>Journal of pediatric hematology/ oncology</i>
2016 Sep	Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.	<i>Journal of clinical oncology</i>
2019 May	Radiation Treatment for Ewing Sarcoma Family of Tumors in Adult Patients: A Single Institution's Experience Over 40 Years.	<i>American journal of clinical oncology</i>
2019 Jul	Emerging trends in immunotherapy for pediatric sarcomas.	<i>Journal of hematology & oncology</i>
2020 Feb	GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas.	<i>American journal of cancer research</i>
2020 Apr	Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.	<i>Sarcoma</i>
2020 Oct	Chordoma of the Clivus and Acute Myeloid Leukemia: Is There a Connection?	<i>Journal of pediatric hematology/ oncology</i>

JOHN LIGON, MD		
DATE	TITLE	JOURNAL
2019 Jul	Invasive fusariosis masquerading as extramedullary disease in rapidly progressive acute lymphoblastic leukemia.	<i>Pediatric blood & cancer</i>
2021 Nov	Immuno-transcriptomic profiling of extracranial pediatric solid malignancies.	<i>Cell reports</i>
2022 Feb	Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions.	<i>Frontiers in immunology</i>
2022 Aug	CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.	<i>Blood</i>
2022 Sep	Fertility and CAR T-cells: Current practice and future directions.	<i>Transplantation and cellular therapy</i>
2022 Dec	The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes.	<i>Blood advances</i>

JORDAN MILNER, MD		
DATE	TITLE	JOURNAL
2018 Sep	B-precursor acute lymphoblastic leukemia complicating 18q deletion syndrome.	<i>Pediatric Blood and Cancer</i>
2021 May	Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation	<i>Bone marrow transplantation</i>
2022 Feb	Significant improvement of child physical and emotional functioning after familial haploidentical stem cell transplant	<i>Bone marrow transplantation</i>
2022 Sep	Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients	<i>Cureus</i>

ELIAS SAYOUR, MD, PHD		
DATE	TITLE	JOURNAL
2016 Feb	Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.	<i>Clinical cancer research</i>
2016 Oct	Bone marrow transplantation for CVID-like humoral immune deficiency associated with red cell aplasia.	<i>Pediatric blood & cancer</i>
2016 Nov	Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.	<i>Oncoimmunology</i>
2017 Jan	Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.	<i>Journal of immunology research</i>
2017 Feb	Translational nanoparticle engineering for cancer vaccines.	<i>Oncoimmunology</i>
2017 Jul	The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma.	<i>Journal of neurosurgery</i>
2017 Oct	Immunotherapy for Pediatric Brain Tumors.	<i>Brain sciences</i>
2017 Nov	CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression.	<i>Frontiers in immunology</i>
2018 Jan	CD70, a novel target of CAR T-cell therapy for gliomas.	<i>Neuro-oncology</i>

2018 Mar	The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas.	<i>Frontiers in molecular neuroscience</i>
2018 Sep	Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes.	<i>International journal of molecular sciences</i>
2018 Oct	Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.	<i>Nano letters</i>
2018 Dec	Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma.	<i>The EMBO journal</i>
2019 Apr	RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors.	<i>Molecular therapy</i>
2019 Jun	Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.	<i>Neuro-oncology</i>
2019 Jul	Emerging trends in immunotherapy for pediatric sarcomas.	<i>Journal of hematology & oncology</i>
2019 Sep	CXCR1- or CXCR2-modified CART T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors.	<i>Nature communications</i>
2019 Oct	Characterization of myeloid-derived suppressor cells and cytokines GM-CSF, IL-10 and MCP-1 in dogs with malignant melanoma receiving a GD3-based immunotherapy.	<i>Veterinary immunology and immunopathology</i>
2019 Nov	Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling.	<i>Journal for immunotherapy of cancer</i>
2019 Dec	Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging.	<i>ACS nano</i>
2020 Feb	Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma.	<i>Cancer research</i>
2020 Feb	GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas.	<i>American journal of cancer research</i>
2021 Jan	Nanoparticles as immunomodulators and translational agents in brain tumors.	<i>Journal of neuro-oncology</i>
2021 Feb	Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.	<i>Veterinary immunology and immunopathology</i>

WILLIAM SLAYTON, MD		
DATE	TITLE	JOURNAL
2016 Sep	Proton Therapy for Pediatric Hodgkin Lymphoma.	<i>Pediatric blood & cancer</i>
2017 Jan	Importance of baseline PET/CT imaging on radiation field design and relapse rates in patients with Hodgkin lymphoma.	<i>Advances in radiation oncology</i>
2018 Aug	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.	<i>Journal of clinical oncology</i>
2019 Jan	Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15R α Signaling.	<i>Current gene therapy</i>
2019 Jun	A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.	<i>Blood advances</i>
2020 Jan	Irradiating Residual Disease to 30 Gy with Proton Therapy in Pediatric Mediastinal Hodgkin Lymphoma.	<i>International journal of particle therapy</i>
2020 Feb	GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas.	<i>American journal of cancer research</i>

2020 Aug	Post Transplant Lymphoproliferative Disorder risk factors in children: Analysis of a 23-year single-institutional experience.	<i>Pediatric transplantation</i>
2020 Oct	How we approach Philadelphia chromosome-positive acute lymphoblastic leukemia in children and young adults.	<i>Pediatric blood & cancer</i>
2020 Oct	Incidence and Risk Factors for 30-Day Readmission after Inpatient Chemotherapy among Acute Lymphoblastic Leukemia Patients.	<i>Healthcare (Basel, Switzerland)</i>
2021 Apr	Eating behaviors and dietary quality in childhood acute lymphoblastic leukemia survivors.	<i>Pediatric blood & cancer</i>
2022 Jan	Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma.	<i>International journal of radiation oncology, biology, physics</i>
2022 Aug	Volunteer-Based Social Support Structures and Program Exposure Outcomes in an Adolescent Young Adult Palliative Care Peer Support Program.	<i>Journal of palliative medicine</i>

TUNG WYNN, MD		
DATE	TITLE	JOURNAL
2018 Feb	Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium.	<i>Cancer treatment reviews</i>
2018 Mar	Late Effects After Radiotherapy for Childhood Low-grade Glioma.	<i>American journal of clinical oncology</i>



**WE BELIEVE IN PROTECTING
TOMORROW'S FUTURES, TODAY!**

WITH GRATITUDE,
YOUR PHILANTHROPY HAS DRAMATICALLY IMPACTED RESEARCH
AND PATIENT CARE FOR YEARS TO COME.
ON BEHALF OF OUR FACULTY AND THE PATIENTS THEY WILL SERVE,
THANK YOU FOR YOUR GENEROSITY.

For more information, please contact:

Margaret Friend
Executive Director of Development
UF Health Advancement
352-265-7277 direct
352-745-2420 cell
frienm@shands.ufl.edu
giving.UFHealth.org